title: Medicine. The need for a global HIV vaccine enterprise.
abstract: A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.
authors.affiliation: Bill and Melinda Gates Foundation, Seattle, WA 98102, USA.
authors.forename: Richard D
authors.initials: RD
authors.lastname: Klausner
authors.forename: Anthony S
authors.initials: AS
authors.lastname: Fauci
authors.forename: Lawrence
authors.initials: L
authors.lastname: Corey
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: Helene
authors.initials: H
authors.lastname: Gayle
authors.forename: Seth
authors.initials: S
authors.lastname: Berkley
authors.forename: Barton F
authors.initials: BF
authors.lastname: Haynes
authors.forename: David
authors.initials: D
authors.lastname: Baltimore
authors.forename: Chris
authors.initials: C
authors.lastname: Collins
authors.forename: R Gordon
authors.initials: RG
authors.lastname: Douglas
authors.forename: Jose
authors.initials: J
authors.lastname: Esparza
authors.forename: Donald P
authors.initials: DP
authors.lastname: Francis
authors.forename: N K
authors.initials: NK
authors.lastname: Ganguly
authors.forename: Julie Louise
authors.initials: JL
authors.lastname: Gerberding
authors.forename: Margaret I
authors.initials: MI
authors.lastname: Johnston
authors.forename: Michel D
authors.initials: MD
authors.lastname: Kazatchkine
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: McMichael
authors.forename: Malegapuru W
authors.initials: MW
authors.lastname: Makgoba
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pantaleo
authors.forename: Peter
authors.initials: P
authors.lastname: Piot
authors.forename: Yiming
authors.initials: Y
authors.lastname: Shao
authors.forename: Edmund
authors.initials: E
authors.lastname: Tramont
authors.forename: Harold
authors.initials: H
authors.lastname: Varmus
authors.forename: Judith N
authors.initials: JN
authors.lastname: Wasserheit
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000191:economics / Q000276:immunology; D000047:Academies and Institutes / Q000191:economics / Q000458:organization & administration; D001709:Biotechnology / Q000191:economics; D002986:Clinical Trials as Topic / Q000592:standards; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000592:standards; D004345:Drug Industry / Q000191:economics; D005378:Financial Support; D014943:Global Health; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018973:Intellectual Property; D007391:International Cooperation; D015337:Multicenter Studies as Topic; D017149:Private Sector; D011640:Public Policy; D017150:Public Sector; D012109:Research Support as Topic; D014611:Vaccination
chemical_list: D016915:AIDS Vaccines